Search research articles
Contact Us
Filters
Showing results (131-140 of 268) with videos related to
Page
of 27
Sort By:
Journal of Neuroinflammation
|
September 1, 2022
IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes
Florent Lemaître, Negar Farzam-Kia, Ana Carmena Moratalla, et al.
Frontiers in Neurology
|
August 8, 2024
Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial
Amel Zertal, Kanza Alami Marrouni, Nathalie Arbour, et al.
Cell Death & Disease
|
February 6, 2019
Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology
Claudio Derada Troletti, Ruud D Fontijn, Elizabeth Gowing, et al.
Nature Immunology
|
December 25, 2007
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system
Romain Cayrol, Karolina Wosik, Jennifer L Berard, et al.
Journal of Autoimmunity
|
June 24, 2017
Targeting the GM-CSF receptor for the treatment of CNS autoimmunity
Igal Ifergan, Todd S Davidson, Hania Kebir, et al.
Cellular & Molecular Immunology
|
January 13, 2019
CD70 defines a subset of proinflammatory and CNS-pathogenic T<sub>H</sub>1/T<sub>H</sub>17 lymphocytes and is overexpressed in multiple sclerosis
Tessa Dhaeze, Laurence Tremblay, Catherine Lachance, et al.
Neurology and Therapy
|
July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management
|
April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study
Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Page
of 27
Search research articles
Search
Showing results (131-140 of 268) with videos related to
Sort By:
Page
of 27
Journal of Neuroinflammation
|
September 1, 2022
IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes
Florent Lemaître, Negar Farzam-Kia, Ana Carmena Moratalla, et al.
Frontiers in Neurology
|
August 8, 2024
Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial
Amel Zertal, Kanza Alami Marrouni, Nathalie Arbour, et al.
Cell Death & Disease
|
February 6, 2019
Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology
Claudio Derada Troletti, Ruud D Fontijn, Elizabeth Gowing, et al.
Nature Immunology
|
December 25, 2007
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system
Romain Cayrol, Karolina Wosik, Jennifer L Berard, et al.
Journal of Autoimmunity
|
June 24, 2017
Targeting the GM-CSF receptor for the treatment of CNS autoimmunity
Igal Ifergan, Todd S Davidson, Hania Kebir, et al.
Cellular & Molecular Immunology
|
January 13, 2019
CD70 defines a subset of proinflammatory and CNS-pathogenic T<sub>H</sub>1/T<sub>H</sub>17 lymphocytes and is overexpressed in multiple sclerosis
Tessa Dhaeze, Laurence Tremblay, Catherine Lachance, et al.
Neurology and Therapy
|
July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management
|
April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study
Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Page
of 27